Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Clinical A/Prof Lauren Sanders

Clinical A/Prof Lauren Sanders

Migraine Management Update

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Asthma Cases – When to Use Dual vs Triple Therapy

Dr Johanna Lynch

Dr Johanna Lynch

Trauma-Informed Care in GP

Prof Richard O'Brien

Prof Richard O'Brien

Prevention and Management of Diabetic Retinopathy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Martin MacDonald

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023